SCHEMBL4915532

SCHEMBL4915532

CCOC(=O)c1ccc(NC(=O)Nc2cccc(-c3ccnc(C)n3)c2)cc1

nearest known ligand 0.70

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
MAPT P10636 9/20 0.70
TRPV1 Q8NER1 2/20 0.59
MEN1 O00255 4/20 0.55
KMT2A Q03164 4/20 0.55
NPC1 O15118 3/20 0.55
RAB9A P51151 3/20 0.55
SMN1; SMN2 Q16637 3/20 0.55
CYP3A4 P08684 1/20 0.55
GAA P10253 1/20 0.52
CASP3 P42574 1/20 0.51
SENP7 Q9BQF6 1/20 0.51
CNR1 P21554 2/20 0.51
DNMT3B Q9UBC3 1/20 0.49
USP2 O75604 1/20 0.49
LMNA P02545 1/20 0.49
MAPK1 P28482 1/20 0.49
SYK P43405 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4911322 0.89 NPC1 (0.59) MAPTTRPV1MEN1KMT2ANPC1
SCHEMBL5176441 0.89 MAPT (0.56) MAPTTRPV1MEN1KMT2ANPC1
SCHEMBL4123352 0.84 MAPT (0.82) MAPTNPC1RAB9ACNR1DNMT3B
SCHEMBL4921357 0.84 MAPT (0.82) MAPTRAB9ACNR1DNMT3BLMNA
SCHEMBL4912509 0.82 MAPT (1.00) MAPTCNR1
SCHEMBL4922831 0.82 MAPT (0.79) MAPTKMT2ANPC1RAB9ASMN1; SMN2
Hydrochloric Acid SCHEMBL4915559 0.81 MAPT (0.98) MAPTCNR1
SCHEMBL4118606 0.81 MAPT (0.76) MAPTMEN1KMT2ANPC1RAB9A
SCHEMBL4119185 0.79 MAPT (0.70) MAPTMEN1KMT2ASMN1; SMN2CNR1
SCHEMBL5175995 0.79 MEN1 (0.59) MAPTTRPV1MEN1KMT2ANPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120214808-A1 Aryl Urea Derivatives for Treating Obesity PROSIDION LIMITED (GB) 2012-08-23 US claimed
US-20080261952-A1 Aryl Urea Derivatives for Treating Obesity PROSIDION LTD. (GB) 2008-10-23 US claimed
EP-1786422-A2 ARYL UREA DERIVATIVES FOR TREATING OBESITY Prosidion Limited (GB) 2007-05-23 EP claimed
WO-2006018662-A2 ARYL UREA DERIVATIVES FOR TREATING OBESITY PROSIDION LIMITED (GB) 2006-02-23 WO claimed
US-20120214808-A1 Aryl Urea Derivatives for Treating Obesity PROSIDION LIMITED (GB) 2012-08-23 US disclosed
US-20120214808-A1 Aryl Urea Derivatives for Treating Obesity PROSIDION LIMITED (GB) 2012-08-23 US disclosed
US-20080261952-A1 Aryl Urea Derivatives for Treating Obesity PROSIDION LTD. (GB) 2008-10-23 US disclosed
US-20080261952-A1 Aryl Urea Derivatives for Treating Obesity PROSIDION LTD. (GB) 2008-10-23 US disclosed
US-20080261952-A1 Aryl Urea Derivatives for Treating Obesity PROSIDION LTD. (GB) 2008-10-23 US disclosed
EP-1786422-A2 ARYL UREA DERIVATIVES FOR TREATING OBESITY Prosidion Limited (GB) 2007-05-23 EP disclosed
WO-2006018662-A2 ARYL UREA DERIVATIVES FOR TREATING OBESITY PROSIDION LIMITED (GB) 2006-02-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080261952-A1 Aryl Urea Derivatives for Treating Obesity CNR1, GPR119, UTS2R MAPT 4151/4885TRPV1 446/4885MEN1 4843/4885
US-20120214808-A1 Aryl Urea Derivatives for Treating Obesity CNR1, GPR119, UTS2R MAPT 4151/4885TRPV1 446/4885MEN1 4843/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.